Christopher Paschen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Paschen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Eva Katharina Masel
Division of Palliative Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria
2 shared publications - Alexander Hermann
Intensive Care Unit 13i2, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Alice Schmidt
Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria
1 shared publication Andja Bojic
From the Department of Internal Medicine I, Intensive Care Unit, Medical University of Vienna, Vienna, Austria
1 shared publicationAndrew Rees
Department of Pathology (M.C.K., H.S., M.N., J.K., A.O., N.K., A.R., R.K., H.R.), Medical University of Vienna, Austria
1 shared publication- André Oszwald
Department of Pathology, Medical University of Vienna, Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 5 (4)
Disappointment and/or a glimmer of hope? - When biochemical efficacy does not translate into (primary) clinical benefit
- 30 October 2026
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 5 (4)
Open AccessDisappointment and/or a glimmer of hope? - When biochemical efficacy does not translate into (primary) clinical benefit
- Open Access
- 19 June 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 140, 106384
Determinants of time to first palliative care consultation in hospitalized patients with advanced or terminal illness – A retrospective analysis
- 19 June 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 140, 106384
Open AccessDeterminants of time to first palliative care consultation in hospitalized patients with advanced or terminal illness – A retrospective analysis
- 1 June 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (6) , 1071-1080
Association of Podometric Findings in Patients With Hypertension and Type 2 Diabetes: A Retrospective Analysis
BACKGROUND: Arterial hypertension (HTN) and type 2 diabetes (T2DM) are contributors to chronic kidney disease leading to glomerulomegaly and podocyte loss. Enlarged glomeruli and podocyte depletion are associated with kidney disease progression. This retrospective study aimed to investigate morphometric changes in patients with HTN and the contribution of coexisting T2DM in HTN. METHODS: Glomerular and podocyte structure was estimated stereologically in unaffected areas of tumor nephrectomies in 99 patients. Morphometric features between subjects with HTN (n=47), HTN+T2DM (n=32), and controls without HTN and T2DM (n=20) were compared by ANOVA. Linear regression models evaluated the effect of morphometric parameters on renal compensation after nephrectomy (change of estimated glomerular filtration rate from pre-nephrectomy to 12 months post-nephrectomy). RESULTS: In total, 36% of the HTN and 50% of the patients with T2DM exhibited dipstick-positive proteinuria. Glomerular volume in HTN+T2DM was similar compared with controls (2.7±0.8 versus 2.3±0.8×10 6 µm³; P =0.16) and to HTN only (2.7±0.9×10 6 µm³; P =0.95). Podocyte density was reduced in HTN+T2DM versus controls (217±66 versus 279±75 per 10 6 µm³; P =0.02) and not different to HTN only (233±87 per 10 6 µm³; P =0.67). Podocyte nuclear volume was larger in HTN+T2DM versus controls (230±28 versus 201±32 µm³; P =0.004) and similar to HTN (221±33 µm³; P =0.39). Larger glomerular volume ( P =0.009), reduced podocyte density ( P =0.003), and nuclear hypertrophy ( P =0.01) were associated with impaired compensation. CONCLUSION: The patterns of podocyte depletion and nuclear hypertrophy were independently observed in both HTN and HTN+T2DM versus controls. Coexisting T2DM exhibited no additional contribution to glomerular and podocyte alterations.
- 1 June 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (6) , 1071-1080
Association of Podometric Findings in Patients With Hypertension and Type 2 Diabetes: A Retrospective Analysis
BACKGROUND: Arterial hypertension (HTN) and type 2 diabetes (T2DM) are contributors to chronic kidney disease leading to glomerulomegaly and podocyte loss. Enlarged glomeruli and podocyte depletion are associated with kidney disease progression. This retrospective study aimed to investigate morphometric changes in patients with HTN and the contribution of coexisting T2DM in HTN. METHODS: Glomerular and podocyte structure was estimated stereologically in unaffected areas of tumor nephrectomies in 99 patients. Morphometric features between subjects with HTN (n=47), HTN+T2DM (n=32), and controls without HTN and T2DM (n=20) were compared by ANOVA. Linear regression models evaluated the effect of morphometric parameters on renal compensation after nephrectomy (change of estimated glomerular filtration rate from pre-nephrectomy to 12 months post-nephrectomy). RESULTS: In total, 36% of the HTN and 50% of the patients with T2DM exhibited dipstick-positive proteinuria. Glomerular volume in HTN+T2DM was similar compared with controls (2.7±0.8 versus 2.3±0.8×10 6 µm³; P =0.16) and to HTN only (2.7±0.9×10 6 µm³; P =0.95). Podocyte density was reduced in HTN+T2DM versus controls (217±66 versus 279±75 per 10 6 µm³; P =0.02) and not different to HTN only (233±87 per 10 6 µm³; P =0.67). Podocyte nuclear volume was larger in HTN+T2DM versus controls (230±28 versus 201±32 µm³; P =0.004) and similar to HTN (221±33 µm³; P =0.39). Larger glomerular volume ( P =0.009), reduced podocyte density ( P =0.003), and nuclear hypertrophy ( P =0.01) were associated with impaired compensation. CONCLUSION: The patterns of podocyte depletion and nuclear hypertrophy were independently observed in both HTN and HTN+T2DM versus controls. Coexisting T2DM exhibited no additional contribution to glomerular and podocyte alterations.
- Open Access
- 17 July 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (8) , 1-9
Timely integration of palliative care. the reality check. a retrospective analysis
Purpose: A large volume of literature suggests that timely integration of palliative care (PC) enhances the well-being, quality of life and satisfaction of patients and their families. It may also positively impact clinical outcomes and healthcare costs throughout the disease trajectory. Therefore, reviewing clinical practice to reflect real-life situations regarding timely PC integration is essential. Methods: This study, conducted at the Vienna General Hospital between March 2016 and August 2022, retrospectively examined PC consultation (PCC) requests. It aimed to assess the timeliness of PC integration by analysing the duration between diagnosis and the first PCC request, as well as the interval between the first PCC request and death. Results: This study included 895 PCCs. The median time from diagnosis to the first PCC was 16.6 (interquartile range (IQR): 3.9–48.4) months, while the median time from the first PCC to death was 17.2 (IQR: 6.1–50.7) days. The median time from diagnosis to first PCC was 10.4 months in females (confidence interval (CI): 6.0–14.8) compared to 10.6 months in males (CI: 8.1–13.1; p = 0.675). There were no gender disparities in the time from first PCC to death, with a median of 23.3 days (CI: 15.6–31.0) for females and 22.3 days (CI: 16.2–28.4) for males (p = 0.93). Fifty percent of patients died between 5 and 47 days after the first PCC. Conclusion: These findings highlight the discrepancy between the clinical perception of PC as end-of-life care and the existing literature, thereby emphasising the importance of timely PC integration.
- 17 July 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (8) , 1-9
Open AccessTimely integration of palliative care. the reality check. a retrospective analysis
Purpose: A large volume of literature suggests that timely integration of palliative care (PC) enhances the well-being, quality of life and satisfaction of patients and their families. It may also positively impact clinical outcomes and healthcare costs throughout the disease trajectory. Therefore, reviewing clinical practice to reflect real-life situations regarding timely PC integration is essential. Methods: This study, conducted at the Vienna General Hospital between March 2016 and August 2022, retrospectively examined PC consultation (PCC) requests. It aimed to assess the timeliness of PC integration by analysing the duration between diagnosis and the first PCC request, as well as the interval between the first PCC request and death. Results: This study included 895 PCCs. The median time from diagnosis to the first PCC was 16.6 (interquartile range (IQR): 3.9–48.4) months, while the median time from the first PCC to death was 17.2 (IQR: 6.1–50.7) days. The median time from diagnosis to first PCC was 10.4 months in females (confidence interval (CI): 6.0–14.8) compared to 10.6 months in males (CI: 8.1–13.1; p = 0.675). There were no gender disparities in the time from first PCC to death, with a median of 23.3 days (CI: 15.6–31.0) for females and 22.3 days (CI: 16.2–28.4) for males (p = 0.93). Fifty percent of patients died between 5 and 47 days after the first PCC. Conclusion: These findings highlight the discrepancy between the clinical perception of PC as end-of-life care and the existing literature, thereby emphasising the importance of timely PC integration.
- Open Access
- 22 June 2023
- Published by Wiley in Head & Neck
- Vol. 45 (8) , 2087-2097
Effect of mannitol‐based reduced‐volume hydration on kidney function in concomitant cisplatin‐based chemoradiation for head‐and‐neck squamous cell carcinoma
Objective: Nephrotoxicity is frequent in cisplatin‐based chemoradiation of head and neck squamous cell carcinoma (HNSCC). Toxicity outcomes and achieved cisplatin‐doses after change of departmental hydration policy are presented.Methods: We performed a retrospective time‐series analysis of HNSCC patients undergoing chemoradiation with conventional hydration (CH) between 01/2017 and 09/2018 versus shorter hydration with mannitol (SHM) between 09/2018 and 08/2019 to compare the rate of acute kidney injury (AKI) and cumulative cisplatin dose.Results: Among 113 HNSCC patients, SHM (n = 35) in comparison to CH (n = 78) correlated with less AKI (54.3% vs. 74.4%; p = 0.034) and higher cisplatin doses (82.9% vs. 61.5% ≥200 mg/m2; p = 0.025). AKI ≥grade 2 was lower with SHM (2.9% vs. CH: 22.8%; p = 0.01). AKI occurred more frequently in females (92.6% vs. males: 60.5%, p = 0.002). Females received lower cumulative cisplatin doses (51.9% vs. males: 73.3%; p = 0.037).Conclusions: We observed less AKI and higher cumulative chemotherapy doses with SHM. Female patients were at higher risk of AKI.
- 22 June 2023
- Published by Wiley in Head & Neck
- Vol. 45 (8) , 2087-2097
Open AccessEffect of mannitol‐based reduced‐volume hydration on kidney function in concomitant cisplatin‐based chemoradiation for head‐and‐neck squamous cell carcinoma
Objective: Nephrotoxicity is frequent in cisplatin‐based chemoradiation of head and neck squamous cell carcinoma (HNSCC). Toxicity outcomes and achieved cisplatin‐doses after change of departmental hydration policy are presented.Methods: We performed a retrospective time‐series analysis of HNSCC patients undergoing chemoradiation with conventional hydration (CH) between 01/2017 and 09/2018 versus shorter hydration with mannitol (SHM) between 09/2018 and 08/2019 to compare the rate of acute kidney injury (AKI) and cumulative cisplatin dose.Results: Among 113 HNSCC patients, SHM (n = 35) in comparison to CH (n = 78) correlated with less AKI (54.3% vs. 74.4%; p = 0.034) and higher cisplatin doses (82.9% vs. 61.5% ≥200 mg/m2; p = 0.025). AKI ≥grade 2 was lower with SHM (2.9% vs. CH: 22.8%; p = 0.01). AKI occurred more frequently in females (92.6% vs. males: 60.5%, p = 0.002). Females received lower cumulative cisplatin doses (51.9% vs. males: 73.3%; p = 0.037).Conclusions: We observed less AKI and higher cumulative chemotherapy doses with SHM. Female patients were at higher risk of AKI.
- 15 February 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (11) , 1372-1378
In Vivo Suction Pressures of Venous Cannulas During Veno-venous Extracorporeal Membrane Oxygenation
Extracorporeal lung support includes the risk of hemolysis due to suction pressures. Manufacturers measure the negative suction pressure across drainage cannulas for their products in vitro using water. Clinical experience suggests that hemolysis occurs in vivo already at much lower flow rates. The aim of this study was to analyze the in vivo suction pressure for veno-venous extracorporeal membrane oxygenation (VV-ECMO) cannulas. Prospective, observational study at a tertiary-care intensive care unit: 15 patients on VV-ECMO for severe ARDS were prospectively included. In vitro, the 25 Fr drainage cannula pressure drops below a critical level of around –100 mm Hg at a flow rate of 7.9 L/min, the 23 Fr drainage cannula at 6.6 L/min. In the clinical setting, critical suction pressures were reached at much lower flow rates (5.5 and 4.7 L/min; p < 0.0001, nonlinear regression). The in vitro data largely overestimate the safely achievable flow rates in daily clinical practice by 2.4 L/min (or 44%, 25 Fr) and 1.9 L/min (or 41%, 23 Fr). In vivo measurement of suction pressure of venous drainage cannulas differed significantly from in vitro derived measurements as the latter largely underestimate the resulting suction pressure.
- 15 February 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (11) , 1372-1378
In Vivo Suction Pressures of Venous Cannulas During Veno-venous Extracorporeal Membrane Oxygenation
Extracorporeal lung support includes the risk of hemolysis due to suction pressures. Manufacturers measure the negative suction pressure across drainage cannulas for their products in vitro using water. Clinical experience suggests that hemolysis occurs in vivo already at much lower flow rates. The aim of this study was to analyze the in vivo suction pressure for veno-venous extracorporeal membrane oxygenation (VV-ECMO) cannulas. Prospective, observational study at a tertiary-care intensive care unit: 15 patients on VV-ECMO for severe ARDS were prospectively included. In vitro, the 25 Fr drainage cannula pressure drops below a critical level of around –100 mm Hg at a flow rate of 7.9 L/min, the 23 Fr drainage cannula at 6.6 L/min. In the clinical setting, critical suction pressures were reached at much lower flow rates (5.5 and 4.7 L/min; p < 0.0001, nonlinear regression). The in vitro data largely overestimate the safely achievable flow rates in daily clinical practice by 2.4 L/min (or 44%, 25 Fr) and 1.9 L/min (or 41%, 23 Fr). In vivo measurement of suction pressure of venous drainage cannulas differed significantly from in vitro derived measurements as the latter largely underestimate the resulting suction pressure.